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AKTIVITI- AKTIVITI FIBRINOLISIS DAN HEMOSTATIK ASID KAFEIK 
ESTER FENETIL (CAPE) DAN PROPOLIS DARI LEBAH KELULUT 
MALAYSIA DAN POPLAR ROMANIA IN VITRO 
 
ABSTRAK 
 
Ester fenetil asid kafeik (CAPE) diambil daripada propolis dan tumbuh-tumbuhan.  
Tujuan kajian ini termasuk: (1) membangunkan dan validasi prosedur lisis bekuan 
darah utuh (DU) in vitro untuk kajian-kajian fibrinolitik, (2) Kajian aktiviti 
fibrinolitik, antiplatlet dan antikoagulasi CAPE, Tetratrigona itama (T.itama) 
Malaysia dan propolis poplar dan (3) Mengenalpasti dan menentukan kandungan 
CAPE propolis T.itama Malaysia. 
 
Prosedur lisis bekuan DU dibangunkan menggunakan kaedah bekuan DU yang 
mengecut dan dieram dalam takungan platlet yang kekurangan plasma (PKP) 
mengikut pelbagai masa pengeraman. Prosedur ini berjaya divalidasi menggunakan 
streptokinase (SK). Aktiviti fibrinolik dinilai menggunakan D-Dimer (DD), 
morfologi fibrin menggunakan mikroskopi  konfokal dan berat bekuan DU. DD 
diukur secara fotometrik melalui kaedah imun-turbidometrik. Aktiviti fibrinolitik 
CAPE, T.itama Malaysia dan propolis poplar dinilai menggunakan prosedur lisis 
bekuan DU pada kepekatan yang berlainan.  Kajian aktiviti platlet CAPE dijalankan 
dengan esei in vitro yang berbeza termasuklah: 1) pengukuran aggregasi platlet oleh 
agregometri menggunakan pelbagai agonis termasuk adenosine difosfat (ADP), asid 
arakidonik (AA) dan ristosetin. 
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2) Pengukuran penanda pengaktifan platlet (PAC-1 dan P-selectin) oleh sitometri 
aliran. 3) Penentuan reseptor P2Y12 oleh teknik blot Barat.  Kajian platlet T. Itama 
Malaysia dan propolis poplar dibuat dengan agregometri platlet.  Parameter TEG 
direkodkan selepas eraman (inkubasi) CAPE, T.itama Malaysia dan propolis poplar 
dalam DU. Pengukuran kandungan CAPE dalam propolis dilakukan oleh analisis 
GC-MS menggunakan lekukan kalibrasi yang dibina di atas kawasan puncak 
berlawanan dengan kepekatan CAPE yang berbeza. 
 
Untuk kajian aktiviti fibrinolitik, terdapat perbezaan purata tahap DD (ug/ml) 
berbeza secara signifikan (p< 0.05) merentasi sampel yang dieram dengan CAPE 
dalam pelbagai kepekatan. Juga terdapat perbezaan DD untuk kedua-dua jenis 
propolis dibandingkan dengan kawalan normal (PKP). Jisim median sebelum dan 
selepas inkubasi bekuan DU (gm) CAPE menurun, begitu juga untuk T.itama 
Malaysia dan propolis poplar. Morfologi fibrin dibuat secara mikroskopik dan 
menunjukkan kesan kebergantungan dos CAPE. Lima puluh peratus keberkesanan 
dos (ED50) CAPE (menggunakan DD) adalah 1.99 mg/ml.  
 
 Terdapat kesan anti-platlet dengan teknik yang digunakan dalam kaedah ini. CAPE, 
T.itama Malaysia dan propolis poplar ED50 (berdasarkan agregasi platlet) adalah 
masing-masing 7.31 µg/ml, 0.79 mg/ml dan 0.86 mg/ml. Keputusan TEG 
menunjukkan parameter fibrinolitik (LY30) berbeza (p<0.17) daripada kawalan 
normal sampel yang dieram dalam kepekatan CAPE T.itama Malaysia dan propolis 
poplar yang berbeza.  Kesan anti-platlet CAPE mungkin menyebabkan pengurangan 
nilai MA pada esei TEG. Kuantiti CAPE yang diukur pada T.itama Malaysia dan 
propolis poplar adalah : 0.6 (0.1) dan 29.7 (1.2) mg/g. 
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Kajian ini mencadangkan CAPE, T.itama Malaysia dan propolis poplar mempunyai 
aktiviti fibrinolitik dan anti-platlet melalui kaedah in vitro. Walaubagaimanapun 
tiada kesan antikoagulasi seperti yang dikesan oleh esei TEG. Kajian seterusnya 
untuk CAPE dan propolis sebagai potensi ejen alternative hemostatik perlu diadakan 
pada masa hadapan. 
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FIBRINOLYTIC AND HAEMOSTATIC ACTIVITIES OF CAFFEIC ACID 
PHENETHYL ESTER AND PROPOLIS FROM MALAYSIAN STINGLESS 
BEE AND ROMANIAN POPLAR IN VITRO 
 
ABSTRACT 
 
Caffeic acid phenethyl ester (CAPE) is a phenolic derivative from propolis and 
plants. The aims of this study include: (1) Development and validation of an in vitro 
whole blood (WB) clot lysis procedure for fibrinolytic activity study, (2) 
Investigation of fibrinolytic, antiplatelet and anticoagulant properties of CAPE, 
Malaysian Tetratrigona itama (T.itama) and poplar propolis and (3) Determination 
and quantification of CAPE compound in Malaysian T.itama propolis. 
 
The WB clot lysis procedure was developed using a standardized unresected 
retracted WB clot incubated in pooled platelet poor plasma (PPP) for varying 
incubation times and successfully validated using streptokinase (SK). The fibrinolyic 
activity was assessed by D-Dimer (DD), fibrin morphology by confocal microscopy 
and WB clot weight. DD was measured photometrically by immuno-turbidometric 
method.  Fibrinolytic activity of CAPE, Malaysian T.itama and poplar propolis was 
assessed by the new WB clot lysis procedure at different concentrations and different 
times.  Platelet activity study of CAPE was performed using different in vitro assays 
including: 1) Platelet aggregation measurement by platelet aggregometry with 
different types of agonists, adenosine diphosphate (ADP), arachidonic acid (AA) and 
ristocetin. 2) Platelet activation markers (PAC-1 and P-selectin) expression by flow 
cytometry. 3) P2Y12 receptor determination by Western blot (W.blot) technique. The 
xxviii 
 
platelet study of Malaysian T.itama and poplar propolis was done by platelet 
aggregometry. Thromboelastgraphy (TEG) parameters were recorded following WB 
incubation with CAPE, Malaysian T.itama and poplar propolis. Quantitation of 
CAPE in propolis was performed by Gas Chromatograph-Mass Spectrometer (GC-
MS) analysis using constructed calibration curves on peak area versus various 
concentrations of CAPE.  
 
The mean differences of DD (µg/ml) levels were significantly different (p<0.05) 
across samples incubated with different CAPE concentrations and both types of 
propolis compared with normal control (PPP). The median pre and post-incubation 
WB clot weights (gm) were significantly decreased for CAPE, Malaysian T.itama 
and poplar propolis. Fibrin removal was observed microscopically and indicated 
dose-dependent effects of CAPE compared with that of normal control at different 
time. The 50% effective dose (ED50) of CAPE (based on DD) was 1.99 mg/ml.  
 
The anti-platelet effect was observed by the techniques used in this study for CAPE 
and both propolis. The ED50 of CAPE, Malaysian T.itama and poplar propolis 
(based on platelet aggregation) was 7.31 µg/ml, 0.79 mg/ml and 0.86 mg/ml 
respectively. TEG results showed fibrinolytic parameter (LY30), was significantly 
different (p<0.17) from normal control samples incubated in different concentrations 
of CAPE, Malaysian T.itama and poplar propolis. The antiplatelet effect of CAPE 
may have contributed to the reduced maximum amplitude (MA) value of TEG assay. 
The quantity of CAPE measured in Malaysian T.itama and poplar propolis were: 
0.6 (0.1) and 29.7 (1.2) mg/g respectively.  
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This study suggests that CAPE, Malaysian T.itama and poplar propolis possess 
fibrinolytic and antiplatelet activity by in vitro methods. However there was no 
anticoagulant effect as detected by TEG assay. Further investigation of CAPE and 
propolis as a potential alternative haemostatic agent should be conducted in future. 
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CHAPTER 1 
 
 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 The Haemostatic system 
 
The  term ‘haemostasis’ refers to the normal response of a blood vessel to injury by 
forming a clot that serves to limit haemorrhage (Rasche, 2001). Haemostasis is a 
complex and efficient system that depends  upon  a  complicated  interplay  between  
plasma  coagulation  and  fibrinolytic  factors,  blood  cells,  vessel  walls,  
extracellular  matrix,  as  well  as  haemorheological properties,  such  as  blood 
viscosity  and  blood flow (Takada et al., 1994b). The haemostatic system comprises 
of four compartments: the blood vessels, platelets, coagulation factors, and the 
fibrinolytic system (Chee, 2014). Normal haemostasis is divided into primary and 
secondary haemostasis. 
 
1.1.1 Primary haemostasis 
 
Primary haemostasis occurs when a blood vessel is damaged. The blood is exposed 
to collagen fibers in the basement membrane of the vessel (Figure 1.1). Platelets 
adhere to collagen and become activated. Activated platelets release adenosine 
diphosphate (ADP) and thromboxane which cause the aggregation of more platelets 
to the site of injury. This process of platelet aggregation at the site of injury is called 
primary haemostasis which results in the formation of a platelet plug which attempts 
to stop the flow of blood from the broken vessel. Furthermore, healthy vessels 
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secrete an enzyme called prostacyclin that functions in inhibiting platelet activation 
and aggregation through a number of platelet activation pathways that contribute to 
platelet adhesion, aggregation and activation (Hoffman et al., 2005; Jennings, 2009).  
 
 
 
Figure 1.1 Formation of platelet plug  
 
ADP: adenosine diphosphate. 
[Modiefied from (http://www.biosbcc.net/doohan/sample/htm/Hemostasis.htm)]. 
 
1.1.1.1 Platelet activation pathways  
 
Platelet activation occurs through multiple pathways which include collagen, ADP, 
thromboxane A2, epinephrine, serotonin and thrombin (Figure 1.2 and Table 1.1) 
(Scarano et al., 1997; Offermanns, 2006; Davì and Patrono, 2007; Varga-Szabo et al., 
2008; Rivera et al., 2009). ADP is stored in platelets dense granules and released 
from adherent platelets during platelet activation. It participates in platelet activation 
occurring both during primary haemostatic plug (monolayer of platelet) and during 
formation of occlusive platelet-rich thrombus. ADP also enhances platelet 
procoagulant activity through contact with P2Y1 and P2Y12 receptors. 
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Thromboxane A2 is released from adherent platelets and enhances recruitment and 
aggregation for primary plug formation and activates platelets during both protective 
haemostasis and pathologic thrombus formation (Rivera et al., 2009).  
 
Collagen is a strong thrombogenic substrate. Under high-shear conditions, platelet 
adhesion is mediated by the binding of Von Willebrand factor (vWF) located on 
collagen or on the surface of activated platelets to GPIb. Subsequently, this 
interaction leads to activation of GPIIb/IIIa and to stabilize vWF-mediated platelet 
aggregates (Varga-Szabo et al., 2008). However, the binding between GPIb and vWF 
is inadequate for stable adhesion and GPVI is the main platelet-collagen receptor that 
mediates platelet activation, which is necessary for adhesion, aggregation, 
degranulation and coagulant activity on the matrix (Varga-Szabo et al., 2008).  
 
Thrombin is the most effective platelet activator of platelets at very low 
concentrations, lower than those required for activating of the coagulation cascade 
(Brummel et al., 2002; Mann et al., 2003). Thrombin binds the protease-activated 
receptor (PAR)-1 on the platelet surface, leading to cleavage of the receptor, and 
exposing a tethered ligand, which binds and activates the receptor (Vu et al., 1991). 
Platelets also express PAR-4, which requires higher concentrations of thrombin for 
activation (Han et al., 2011). Activated platelets promote the catalysis of two 
sequential reactions of the blood coagulation cascade: the activation of factor X into 
factor Xa by a complex of factor IXa, factor VIlla, and Ca
2+
 and the conversion of 
prothrombin into thrombin by a complex of factor Xa, factor Va, and Ca
2+
 (Rosing et 
al., 1985). 
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Antiplatelet agents, including aspirin, thienopyridines and platelet glycoprotein 
GPIIb/IIIa receptor inhibitors, have been developed for the treatment and prevention 
of cardiovascular diseases. However, these agents have several clinical disadvantages 
including gastrointestinal side-effects and haemorrhagic events (Gum et al., 2003; 
Rezkalla and Benz, 2003). 
 
 
Figure 1.2 Major platelet receptor-ligand interactions  
 
ADP: adenosine diphosphate; GP: glycoprotein; PAR: protease-activated receptor; TxA2: 
Thromboxane A2; vWF: von Willebrand factor, [adapted from (Rivera et al., 2009)]. 
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Table 1.1 Agonists - enhanced platelet activation and their effects on platelets  
 
Platelet 
activator 
Receptor(s) Effect on platelets 
 
ADP P2Y1 
P2Y12 
- Platelet shape change (P2Y1)  
- Transient aggregation (P2Y1)  
- Sustained irreversible aggregation 
(P2Y12). 
- Expression of P-selectin (P2Y12)  
- Release of thromboxane A2 (P2Y1 
and P2Y12)  
- Platelet recruitment to sites of injury 
(P2Y12)  
- Induction of procoagulant activity and 
aggregation (P2Y12) 
Thromboxane 
A2 
TPα 
TPβ 
- Platelet recruitment and aggregation to a 
primary platelet plug (TPα) 
Serotonin 5HT-2A - Platelet recruitment to sites of injury  
- Induction of procoagulant activity via 
retention of fibrinogen and thrombo 
spondin on platelet surface 
Epinephrine α2a - Supplementary role overlapping P2Y12 
receptor signaling 
Collagen GPIb (high shear via vWF) 
GPIIb/IIIa (high shear via 
vWF) 
GPIa/IIa (low shear) 
GPVI (low shear) 
- Activation of GPIIb/IIIa 
- Release of ADP and thromboxane A2 
- Platelet spreading 
- Platelet aggregation 
- Induction of procoagulant activity via 
release of  Ca
2+
 
Thrombin PAR- 1 
PAR-4 
- Platelet aggregation (PAR-1)  
- Release of ADP,  thromboxane A2 
(PAR-4), serotonin (PAR-1) and 
epinephrine (PAR-1)  
- Activation/mobilisation of P-selectin 
and CD40 ligand (PAR-1)  
- Induction of platelet procoagulant 
activity (PAR-1) 
 
Receptors primarily responsible for activation in platelets are indicated in bold. ADP: adenosine 
diphosphate; GP: glycoprotein; PAR: protease-activated receptor; vWF: von Willebrand factor, 
[modified  from (Jennings, 2009)].  
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1.1.2 Secondry haemostasis 
 
Secondary haemostasis comprises three phases of coagulation which are the 
initiation phase (exposure of tissue factor to coagulation factors), amplification phase 
(conversion from extrinsic to intrinsic thrombin generation) and propagation phase 
(thrombin generation with fibrin deposition) (Figure 1.3). Secondary haemostasis 
usually starts when a tissue factor (TF) is exposed to blood following endothelial 
damage (Key et al., 2007; Wintrobe and Greer, 2009). Initially, TF forms a complex 
with coagulation factor VII which in turn activates factor IX and factor X. After that 
activated factor X (FXa) forms the prothrombinase complex together with activated 
factor V (FVa) on a phospholipid membrane surface, which is provided by activated 
platelets and microparticles that convert prothrombin into thrombin.  
 
Thrombin can increase its own generation through activating factor XI (FXI) to 
factor XIa (FXIa) which further activates factor IX (FIX) (Butenas and Mann, 2002). 
Factor IX together with activated factor VIII enhances the formation of factor X. 
Thrombin cleaves fibrinogen into fibrin monomers that polymerize and the resultant 
network is stabilized by factor XIIIa-catalyzed cross-linking. The site of vascular 
injury is occluded by a firm fibrin network along with activated platelets. Following 
that, the clot retracts and this retraction may improve the mechanical stability of the 
clots. The  speed  and  degree  of  clot  retraction  are  proportional  to  the  number  
of  platelets (Hoffman et al., 2005). Table 1.2 shows mean plasma factors 
concentrations and properties of coagulation proteins and inhibitors. 
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Figure 1.3 The coagulation cascade. The intrinsic, extrinsic and common 
pathway of coagulation  
 
APTT: activated partial thromboplastin; Ca
++
: calcium; PL: phosphoipid; PT: prothrombin time, 
[modified from (Adams and Bird, 2009)]. 
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Table 1.2 Mean plasma concentrations and properties of coagulation proteins 
and inhibitors  
 
Protein 
Mean plasma 
concentration 
Source Function 
 nM µg/ml   
Prothrombin 1400 100 plasma zymogen 
Factor X 170 10 plasma zymogen 
Factor IX 90 5.1 plasma zymogen 
Factor XI 30 4.8 plasma zymogen 
Factor XIII 90 30 plasma zymogen 
Factor VII 10 0.5 plasma zymogen 
Protein C 60 3.7 plasma zymogen 
Factor V 20 6.6 plasma procofactor 
Factor VIII 0.7 0.2 plasma procofactor 
Factor VIIa 0.1 0.005 endothelium enzyme 
Tissue factor NA NA endothelium cofactor 
Thrombomodulin NA NA plasma cofactor 
Antithrombin III 3400 200 plasma inhibitor 
Protein S 300 21 plasma inhibitor/cofactor 
TFPI 2.5 0.1 plasma inhibitor 
Fibrinogen 7600 2600 plasma precursor 
 
Note: NA: not applicable (membrane protein). 
TFPI: tissue factor pathway inhibitor, [modified from (Butenas and Mann, 2002)]. 
 
1.1.3 The Fibrinolytic system  
 
Fibrinolysis is an essential process for the degradation of the solid-phase fibrin 
network formed by activation due to haemostasic mechanisms. The fibrin clot is 
formed either in the situation of appropriate activation in response to vascular trauma, 
or in pathological thrombosis (arterial or venous) and atherosclerosis (Romanic et al., 
1998). The essential mediator of fibrinolysis is plasmin, which cleaves fibrin at 
specific lysine and arginine residues, leading to the production of fibrin degradation 
products such as X, Y, D, and E (Ittyerah et al., 1979; Wintrobe and Greer, 2009). 
Fibrinolysis is initiated by either one of the two plasminogen activators (PA), 
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urokinase-type plasminogen activator (u-PA) or tissue-plasminogen activator (t-PA). 
Figure 1.4 shows fibrin formation and fibrinolysis. 
 
D-dimer (DD) is a clinically useful marker for exclusion of venous thromboembolism 
(VTE) and evaluating the risk of its recurrence in selected patients’ populations. It is 
formed by the action of three enzymes which are thrombin, factor XIIIa and plasmin. 
Firstly, the fibrinogen is cleaved by thrombin to produce fibrin monomers. Following 
that, thrombin activates factor XIII to the active transglutaminase, factor XIIIa which 
leads to fibrin polymerization. Finally plasmin degrades the crosslinked fibrin to 
release fibrin degradation products (FDP) and expose the DD antigen (Weisel, 2005; 
Adam et al., 2009). DD is normally not detectable, or is detectable in very low levels 
in human blood or plasma, unless the coagulation system has been activated (Adam 
et al., 2009). DD has a positive predictive value and is helpful in imaging 
investigation triage in acute venous syndromes (Ranasinghe and Bonser, 2010).   
 
This fibrinolytic process is mainly controlled by two homologous proteins i.e. 
plasminogen activator inhibitor type-1 (PAI-1), which rapidly complexes with tissue 
t-PA, and α2-antiplasmin, which acts as a specific and rapid inhibitor of plasmin 
(Abdullah et al., 2009). Another natural inhibitor thrombin activated fibrinolysis 
inhibitor (TAFI) is a non-serpin fibrinolysis inhibitor which is activated by 
thrombomodulin-associated thrombin (Broze and Higuchi, 1996; Mosnier et al., 
2001; Chapin and Hajjar, 2014).  
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Figure 1.4 Basic scheme of fibrin clot polymerization and fibrinolysis  
 
[Modified  from (Weisel, 2005)] 
 
The disturbances in hemostatic balance may result in inappropriate clot formation 
inside the blood vessels (thrombosis), or defect in the coagulation activity which may 
lead to bleeding (Takada et al., 1994b; Wolberg et al., 2012). Fibrin and platelets 
form the basic structure of a thrombus/blood clot, and red cells can be entrapped in 
the fibrin clot (Furie and Furie, 2008; Mackman, 2012). The fibrin clot will be lysed 
by the fibrinolytic process and this will allow the vascular lumen patency (Hoylaerts 
et al., 1982). In acute myocardial infarction, the time for antithrombotic therapy or 
fibrinolytic agent administration is very critical to restore the organ function. The 
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fibrinolytic therapy appears to be beneficial for at least 12 hrs following the onset of 
symptoms. However, fibrinolytic therapy for stroke has proven beneficial only when 
used within 3 hrs (Mackman, 2008). 
 
In order to detect the effect of thrombolytic drugs, certain products of fibrinolytic 
activity can be measured, such as DD (Wells et al., 2003a; van Belle et al., 2006), 
plasmin-antiplasmin complex (Bayes-Genis et al., 1999; Lindholt et al., 2001), fibrin 
monomers (Horan and Francis, 2001), fibrin polymerization and clot morphology 
(Parise et al., 1993), t-PA and PAI-1  (Boudjeltia et al., 2002)  and 
thromboelastographic (TEG) parameters e.g. LY30. (Zmuda and Neofotistos, 2000; 
Coppell et al., 2006; Marschner et al., 2010; Thakur and Ahmed, 2012).  Figure 1.5 
demonstrates the degradation of cross-linked fibrin specifically into DD derivatives. 
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 Figure 1.5 Degradation of cross-linked fibrin 
 
Digestion/degradation of cross-linked fibrin by plasmin enzyme gives rise to a variety of fragments 
including D dimmers, [modified from (http://www.practical haemostasis.com/Fibrinolysis/d_dimers. 
html)]. 
 
1.1.3.1 Methods used for assessment of fibrinolysis  
 
Different methods have been used to measure the clot lysis activity of thrombolytic 
drugs. Most of these methods had been tested on artificial clots and used ultrasound 
methods, complicated mathematical or computing skills to measure the thrombolytic 
activity of thrombolytic drugs. These methods are costly, and hence not suitable for 
routine clinical practice (Prasad et al., 2006b).  
 
Alternatively, study was conducted using the diluted blood clot lysis time, which 
represented the interaction between the activity of t-PA and PAI-1 to allow the 
measurement of both baseline and stimulated fibrin dissolution. This test is 
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inexpensive and adapted to a single test system. However, it has disadvantages since 
it has a very long subjective procedure and requires continuous monitoring by an 
observer so as to record the clot lysis activity (Urano et al., 1990).   
 
The euglobulin lysis time (ELT) is an old method which was used to measure the 
overall fibrinolysis by mixing the citrated platelet-poor plasma with acid. Certain 
clotting factors are precipited in the form of complexes which is called the 
euglobulin fraction. This fraction contains fibrinogen, PAI-1, t-PA, plasminogen, 
alpha2-antiplasmin and factor VIII which are measured by spectrophotmetry 
(Kowalski et al., 1959). It was reported that the ELT is used in ranking the 
streptokinase activity of five commercial clinical preparations. However, major 
drawbacks of this method include laborious and time consuming procedure for the  
preparation of the euglobulin fraction in addition to instability of the materials used 
(Couto et al., 2004). 
 
Moreover, an in vitro perfusion model was designed to mimic arterial flow 
conditions using mechanical means. A less complete dissolution of a thrombus in 
conjunction with a greater amount of embolic debris was achieved with this 
approach, though the size of these embolic particles was reduced by the addition of a 
thrombolytic agent (Greenberg et al., 2000). Another study has proposed an in vitro 
clot lytic model for assessment of fibrinolytic activity (Prasad et al., 2006b). As this 
model is rather simple, it has a significant limitation because the fibrinolytic activity 
is calculated from clot weight. Many factors were not controlled in the preparation of 
whole blood (WB) clot, which may give false results. 
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Another method utilised ultrasound to enhance thrombolysis. In these studies clot 
mass loss (Δm) was used as an indicator for thrombolysis. It was found that 120 kHz 
ultrasound is effective in enhancing the thrombolytic efficacy of rt-PA at a 
temperature lower than 37
o
C (Shaw et al., 2006b). Similarly, another study used 
fractional clot mass loss (Δm) arising from in vitro human clot model exposed to tPA 
or plasminogen and hypothermia. It also concluded that the temperature changes 
contributed to the improved lytic efficacy of ultrasound enhanced thrombolysis 
(Shaw et al., 2007b). In addition, haemoglobin was used as a fibrinolytic marker to 
detect the fibrinolytic effect of Lonomia achelous caterpillar venom at different 
concentrations in vitro using human WB. The venom and its active fractions degrade 
the clots at a slower rate than the enzymes urokinase plasminogen activator (uPA), t-
PA and plasmin. It is  minimally affected by physiological plasma protease inhibitors 
(Coll-Sangrona and Arocha-Piñango, 1998). 
 
Several in vitro studies of thrombolysis using WB clots enriched with
125
I-fibrinogen 
(
125
I-Fg) suspended in phosphate-buffered saline (PBS) or serum containing the 
fibrinolytic inducers have been performed. The rate of release of 
125
I-fibrinogen 
degradation products (
125
I-FDPs) in the supernatant was taken as a measure of the 
plasmin-dependent degradation of the clot (Carroll et al., 1981; Sabovic et al., 1989; 
Kunitada et al., 1992; Parise et al., 1993). A comparison between two studies using 
different methods for fibrinolytic assessment (haemoglobin relase and 
125
I-Fg) 
revealed that the haemoglobin release method gave higher values of clot lysis. 
Moreover, the release curves were similar to those obtained using the radioactive 
method and showed good correlation when using  the same plasminogen activator 
(Lopez et al., 2000). 
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1.2 Natural products and application in health 
 
For thousands of years, natural products have played a very important role in health 
care and prevention of diseases. The ancient civilizations of the Chinese, Indians and 
North Africans provide written evidences for the use of natural resources for curing 
various diseases (Phillipson, 2001). The use of natural products in treatment of 
various diseases is increasing due to their broader pharmacological activities with 
less adverse effects. Bee products including honey, bees wax, propolis, pollen, bee 
bread, royal jelly, venom and larvae are reported to have various pharmacological 
activities (Krell, 1996). The medical benefit of honey and other bee products was 
mentioned in Verse 69, Surah An-Nahl in Holy Quraan as “Then eat of all the fruits 
and walk in the ways of your Lord submissively. There comes forth from within it a 
beverage of many colours, in which there is healing for men; most surely there is a 
sign in this for a people who reflect”. Phenolic compounds in honey act as natural 
antioxidants and are popular because of their potential roles in human health (Khalil 
and Sulaiman, 2010).  
 
1.2.1 Bee products 
 
Bee products can be classified into two large groups: the products of animal and 
plant origin. Products of plant origin are: honey, bee pollen/breads, propolis, 
gathered by a bee from flowers and stored in the beehive. Products of animal origin 
are: royal jelly, beeswax and bee venom, produced by the bee in the hives. All these 
ingredients are essential to bees, without which bees and the entire bee-hives could 
not sustain (Owayss et al., 2004). 
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Honey was used since ancient times in traditional medicine. It has many biological 
functions such as antibacterial, antioxidant, antitumor, anti-inflamatory, 
antibrowning, and antiviral effects. It is composed of more than 5000 substances and 
is basically a solution supersaturated in sugars, the fructose (38%) and glucose (31%) 
are the most abundant (Gheldof et al., 2002). The moisture content is about 24.30 to 
27%, total acidity 3.1 to 4.1 and ashes constitute 0.06 to 0.08% (Viuda‐Martos et al., 
2010). The composition of honey varies, depending on different factors such as 
pollen source, climate, environmental conditions, and the method used for processing 
(Gheldof et al., 2002; Gómez-Caravaca et al., 2006; Viuda‐Martos et al., 2008). 
 
Royal jelly was demonstrated to have various functional properties such as 
antibacterial activity, anti-inflammatory activity, vasodilative and hypotensive 
activities, disinfectant action, antioxidant activity, antihypercholesterolemic activity, 
and antitumor activity. It is the exclusive food of the queen honeybee and the larvae. 
Royal jelly contains water (50% to 60%), proteins (18%), carbohydrates (15%), 
lipids (3% to 6%), mineral (1.5%) and vitamins together with a large number of 
bioactive substances (Nagai and Inoue, 2004; Viuda‐Martos et al., 2008). 
 
Propolis is one of the most important bee products and of interest to many, 
particulary in this study. Propolis has a higher content of bioactive chemical 
compounds when compared to honey as it contains less sugar and water. Honey is 
more palatable compared to propolis, however propolis has higher potential to be 
processed as a nutraceutical agent by adding to honey or to be developed into 
pharmaceutical agent (De Castro, 2001). 
 
17 
 
1.2.1.1 Propolis 
 
The word propolis was probably coined by Aristotle from the Greek words “pro” 
meaning “in front of” and “polis” meaning “city”. The combined meaning then 
becomes “In front of the City” or “Defender of the City (or Beehive)” and this is how 
bees use propolis (Haile and Dekebo, 2013). It is a gum that is gathered by bees from 
various plants which varies in color from light yellow to dark brown, and may cause 
staining of the comb or frame and  can  found in extracted honey (Burdock, 1998a).  
 
Due to the popularity of using propolis in medicine and other domains, thousands of 
studies were developed from all over the world, studying the chemical composition, 
functions, or different properties of propolis extracts. More than 2700 articles and 
250 books were published in Elsevier journals or publishing house 
(http://www.elsevier.com/), more than 2000 articles in Medline 
(http://www.ncbi.nih.gov/), and more than 1500 studies in Wiley-Blackwell database 
(http://www.onlinelibrary.wiley.com/) (Marghitas et al., 2013). Most of the current 
literature concerning propolis is focused on determining the chemical composition 
and biological activity of propolis, besides determining the botanical and 
geographical origins by analyzing comparatively the resins from which propolis is 
derived (Miguel and Antunes, 2011). 
 
1.2.1.1.1 Physical properties of propolis 
 
Propolis colour and aroma differ according to geographical zones. It is a resin being 
yellowish-green, dark green, or brown in colour depending on its plant source and 
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age with a pleasant flavor of poplar buds, honey, wax and vanilla but it can also have 
a bitter taste. It is hard and brittle when cold, but becomes soft and very sticky when 
warm (Naama et al., 2010; Wagh and Borkar, 2012).  
 
1.2.1.1.2 Chemical composition of propolis  
 
Propolis was found to contain many polyphenolic compounds, flavones, flavonones, 
phenolic acid and esters. It contains about 55 % resins and balsams, 30 % waxes, 10 % 
etheric oils and 5% pollen. The components are rich in vitamins and mineral 
elements (Nikolaev, 1978; Khalil, 2006; Haile and Dekebo, 2013). The materials 
necessary for bees to produce of propolis are substances actively secreted by plants 
as well as substances exuded from wounds in plants such as lipophilic substances on 
leaves and leaf buds, resins, mucilages, gums, lattices, etc. The composition of a 
plant source determines the chemical composition of bee glue (Crane, 1990). The 
most important biologically active chemical constituents of propolis from different 
geographic areas and the corresponding plant sources are shown in Table 1.3 
(Bankova, 2005b).  
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Table 1.3 Propolis types according to their plant origin and their active chemical composition  
 
Propolis type  Geographic origin  Plant source 
Main biologically active 
substances 
References 
Poplar propolis  Europe, North 
America, non-tropic 
regions of Asia 
Populous spp. of 
section Aigeiros, 
most often P. nigra L 
Flavones, flavanones, cinnamic 
acids and their esters 
(Nagy et al., 1986), 
(Greenaway et al., 1990), 
(Bankova et al., 2000),   
Birch propolis Russia Betula verrucosa 
Ehrh. 
Flavones and flavonols (not the 
same as in poplar propolis) 
(Popravko and Sokolov, 1980) 
Green (alecrim) 
propolis 
Brazil Baccharis spp., 
predominantly B. 
dracunculifolia DC. 
Prenylated p-coumaric acids, 
diterpenic acids 
(Marcucci and Bankova, 1999) 
Red (Clusia) 
propolis 
Cuba, Venezuela Clusia spp. Polyprenylated benzophenones (Cuesta-Rubio et al., 2002), 
(Trusheva et al., 2004) 
“Pacific” 
propolis  
Pacific region 
(Okinawa, Taiwan) 
Unknown C-prenylflavanones (Chen et al., 2012), 
(Kumazawa et al., 2004) 
“Canarian” 
propolis  
Canary Islands Unknown Furofuran lignans (Christov et al., 1999) 
 
[Modified from (Bankova, 2005a)]. 
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1.2.1.1.3 Clinical implications and biological properties of propolis  
 
The use of propolis has been reported in 300 BC for health improvement and disease 
prevention and also reported for its broader spectrum of pharmacological activities 
(Toreti et al., 2013). The broader biological and pharmacological properties of 
propolis have attracted researchers’ interest as an alternative medicine for various 
pathological conditions. The Indian stingless bee propolis  has been reported to have 
a  complex nature with 24 chemical compounds (Choudhari et al., 2012).  Data from 
the same study also revealed an antimicrobial activity. The crude methanol extract of 
Thai Apis mellifera propolis showed antibacterial activity for Staphylococcus  aureus 
and Escherichia coli (Boonsai et al., 2014). The Ethiopian crude ethanol  extracted  
Haramaya  propolis  (EEHP)  exhibited antifungal  activities  against  Fusarium  sp., 
Aspergillus niger  and  Colletotrichum  sp. (Haile and Dekebo, 2013). 
 
The chemical and biological properties of polar extracts of cerumen or propolis from 
the Australian stingless bee Tetragonula carbonariain  were investigated using gas 
chromatography-mass spectrometry (GC-MS) analyses and in vitro 5-lipoxygenase 
(5-LOX) cell-free assays. In vitro inhibition of 5-Lox activity by this extract was 
documented (Massaro et al., 2011). Propolis-mediated apoptosis of cancer cells  has 
also been previously reported (Szliszka et al., 2009; Szliszka et al., 2011; Szliszka 
and Krol, 2013) and the ethanol extract of propolis  is reported to have cytotoxic 
effect (Russo et al., 2002; Markiewicz-Zukowska et al., 2013) and anticancer 
properties (Naama et al., 2010).  
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Propolis has been reported to have less toxic and fewer adverse effects than caffeic 
acid phenethyl ester (CAPE). Also it has a low order of acute oral toxicity in mice 
with minimum lethal dose (LD50) ranging from 2000 to 7300 mg/kg (Burdock, 
1998b). The safe concentration for humans was found to be 1.4 mg/kg, or about 70 
mg/day. Another study investigated the treatment of rats with different 
concentrations of propolis from different extracts such as water or ethanol and 
different times of administration. Insignificant  alterations  in triglycerides,  total  
lipids, high-density lipoprotein cholesterol (HDL-cholesterol) concentrations, 
aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) specific 
activities, were observed  (Mani et al., 2006). Additionally, the use of propolis as an 
additive in food and beverages is rapidly increasing in Japan and also in Western 
Countries (Nagaoka et al., 2003; Markiewicz-Żukowska et al., 2012). The same 
studies have reported that propolis improves health and prevents inflammation and 
diseases such as heart disease, diabetes and cancer.  
 
Furthermore, propolis was used broadly in cosmetics (Wagh and Borkar, 2012). It 
was reported as apitherapeutic agent which can generate appropriate biochemical 
environment supporting reepithelization (Olczyk et al., 2013b). Moreover, it 
accelerates chondroitin/dermatan sulfates structure modification which is responsible 
for binding growth factors that play a crucial role in tissue repair (Olczyk et al., 
2013a). Various research studies suggested that propolis can be used in medicine 
(Table1.4).
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                   Table 1.4 Recent studies on application of propolis in medicine  
Geographic origin of 
propolis  
Activity attributed Test performed Reference 
Brazil (southern) Anti-HIV activity In vitro (H9 Lymphocytes) (Ito et al., 2001) 
Brazil Anticancer activity In vivo-mice (pulmonary tumors) (Kimoto et al., 
2001) 
Brazil Anticancer activity In vitro (human tumor cell lines) (Akao et al., 
2003) 
Brazil (group 3 and group 
12) 
Suppression of dioxin In vitro (Park et al., 
2004) 
Chile  Antioxidant and 
anticancer  
In vitro (KB cells-human mouth 
epidermoid carcinoma cells; Caco-
2 cells-human colon 
adenocarcinoma cells) 
(Russo et al., 
2004) 
Brazil Anticancer activity I n vitro and in vivo (retinal 
damage) 
(Inokuchi et al., 
2006) 
Brazil (group 3, group 12, 
and bud resins of botanical 
origin) 
Anticancer activity In vitro (human prostate epithelial 
cells 
(Li et al., 2007) 
Brazil Antiinfluenza virus 
activity 
In vivo -mice (influenza virus (Shimizu et al., 
2008) 
Jordanian Antibacteria In vitro (Darwish et al., 
2013) 
Tunisia Anticancer activity In vitro (cancer cell lines-HT29, 
A549, Hep-2, raw264.7, and Vero) 
(Kouidhi et al., 
2010) 
Brazil (group 12 and 
artepellin C) 
Immunosuppressant In vitro (CD4 T cell) (Cheung et al., 
2011) 
Portugal Anticancer activity In vitro (human renal cancer) (Valente et al., 
2011) 
Israel (Kibbutz Yad 
Mordecai and CAPE) 
Anticancer activity In vitro (human T-cell lines) (Shvarzbeyn and 
Huleihel, 2011) 
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Table 1.4. Continued    
Brazil Anticancer activity In vitro (human breast cancer 
MCF-7 cells) 
(Kamiya et al., 
2012) 
Brazil (group 12 and group 
13) 
Anticancer activity In vitro (human cell lins of 
leukemia) 
(Franchi et al., 
2011) 
CAPE (derived from 
honeybee hive propolis) 
Anticancer activity In vitro (human prostate cancer 
cells) 
(Chuu et al., 
2012) 
Brazil Anticancer activity In vivo mice (skin carcinogenesis) (Yasukawa et 
al., 2012) 
Poland Anticancer activity In vitro (U87MG human 
glioblastoma) 
(Markiewicz-
Żukowska et al., 
2013) 
 
                   [ Modified from (Toreti et al., 2013)
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1.2.1.1.4 Types of propolis  
 
Stingless bees diverged since the Cretaceous times, have 50 times more species than 
Apis and are both distinctive and diverse (David, 2006). Various types of propolis are 
present and depend on geographical and climate zones. Among them are propolis 
derived from Malaysian Tetratrigona (T.itam) which is found in tropical regions and 
contains different types of plant species. Poplar Apis mellifera (A.mellifera) propolis 
is found in Europe, North America, and the non-tropical regions of Asia, for which 
the plant source is Populus sp. of section Aigeiros, most often P. nigra (Marinescu 
and Tamas, 1980). 
 
1.2.1.1.4.1 Malaysian Tetratrigona itama propolis  
 
Propolis is a resinous mixture that is collected from tree buds, sap flows, or other 
botanical sources (Choudhari et al., 2012). Malaysian T.itama belongs to the 
stingless bees group, which are of eusocial insects. It has five different genera, 
namely Melipona, Tetrarigona, Meliponula, Dectylurina and Lestrimelitta. They  
play  an  important  role  in  pollination (Heard, 1999). Trigona  is  the  largest  genus  
of  stingless  bees  found  exclusively in the Neotropics,  from  Mexico  to  Argentina  
and in the Indo Australian  region  from  India, Sri  Lanka  to  Taiwan,  the  Solomon 
Islands, South Indonesia, New Guinea and Australia (Michener, 2000). Previous 
studies reported five species of Trigona in India (Gupta, 2003) and more than 23 
species reported in Malaysia by Malaysian Agricultural Research and Development 
Institute (MARDI). 
